Tiziana Lifesciences Announces Intention to Demerge Its StemPrintER Genomics-Based Personalized Medicine Business as a Separate Listed Company

Ads

You May Also Like

Dynavax Secures $175 Million in Non-Dilutive Debt Financing

Proceeds to be Used to Commercialize HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] in United ...